Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Study Details
Study Description
Brief Summary
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
This is an open label, single-arm, multicenter phase 3 study to evaluate efficacy and safety of the BiTE (bispecific T cell engager) antibody blinatumomab in Chinese adults with relapsed/refractory B-precursor ALL. The study will consist of a screening period, a treatment period, and a follow-up period.
Treatment will consist of up to 5 cycles of blinatumomab. Participants who achieve a bone marrow (BM) response (≤ 5% BM blasts) or CR/CRh*/CRi within 2 induction cycles of treatment may continue to receive up to 3 additional consolidation cycles of blinatumomab. Thirty days after end of the last dose of protocol-specified therapy, participants will have a safety follow-up visit.
If subjects are suitable for allogeneic stem cell transplantation (alloHSCT) after treatment with blinatumomab, they may undergo alloHSCT instead of receiving further consolidation cycles with blinatumomab.
Participants will be followed via clinic visit or telephone contact every 3 months after their safety follow-up visit until death has been observed or a maximum of 2 years after start of treatment, whichever occurs first.
A planned interim analysis to assess efficacy and safety of blinatumomab was to be based on the interim analysis set (N = 90). The efficacious benefit assessment based on an O'Brien-Fleming alpha spending function (O'Brien and Fleming, 1979) with the critical boundary 42.2% at the interim analysis and 39.2% at the primary analysis in CR/CRh* rate. If the interim analysis showed statistically efficacious and overall benefit-risk analysis to be promising per the data review team review, then the interim analysis could become the primary analysis of this study. In addition, the study would continue its enrollment until 120 participants had been enrolled and continued their participation in the study to complete protocol-specified procedures.
The data cutoff date of 12 April 2019 allowed for the 90th participant enrolled before 21 February 2019 to have had the opportunity to complete 2 cycles of treatment and the safety follow-up visit (if the participant had discontinued treatment after 2 cycles).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Blinatumomab Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Drug: Blinatumomab
Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).
A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator.
Other Names:
Drug: Dexamthasone
Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab [Within 2 cycles of treatment (12 weeks)]
A CR is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/μL, and absolute neutrophil count [ANC] > 1,000/μL). CRh* is defined as ≤ 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets > 50,000/μl, and ANC > 500/μl. CR/CRh* rate is defined as the percentage of participants who achieve CR/CRh* within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders. The interim analysis was to become the primary analysis by meeting pre-specified efficacy and safety criteria based on an O'Brien-Fleming alpha spending function with the critical boundary 42.2%. Results for both the interim and final analysis are reported.
Secondary Outcome Measures
- Percentage of Participants With a Hematological Response of Complete Remission (CR) During the First 2 Treatment Cycles With Blinatumomab [Within 2 cycles of treatment (12 weeks)]
A CR is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/μL, and absolute neutrophil count [ANC] > 1,000/μL). CR rate is defined as the percentage of participants who achieved CR within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders. Results for both the interim and final analysis are reported.
- Percentage of Participants With a CR or CRh* or Complete Remission With Incomplete Hematological Recovery Without CRh* (CRi) (CR/CRh*/CRi) During the First 2 Treatment Cycles With Blinatumomab [Within 2 cycles of treatment (12 weeks)]
CRi is defined as ≤ 5% blasts in the bone marrow, no evidence of disease and incomplete recovery of peripheral blood counts: platelets > 100,000/μl or ANC > 1,000/μl (but not both). CR/CRh*/CRi rate is defined as the percentage of participants who achieve CR/CRh*/CRi within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders. Results for both the interim and final analysis are reported.
- Pharmacokinetic (PK) Parameter: Concentration of Blinatumomab at Steady State (Css) [Cycle 1: Days 2, 15, and 29; Cycle 2: Days 2, 15, and 29 (approximately study days 44, 57, and 71)]
Blinatumomab serum concentration was quantified using a validated enzyme- linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 pg/mL. Blinatumomab serum steady-state concentrations (Css) was summarized as the average of the observed concentrations collected after 24 hours from the start of continuous IV infusion for each dose level. Cycle 1 day 2 values represent Css for the initial dose of blinatumomab (9 µg/day). Values collected from other time points were used to calculate Css of 28 µg/day dose in their respective cycles.
- Pharmacokinetic (PK) Parameter: Clearance [Cycle 1: Days 2, 15 and 29; Cycle 2: Days 2, 15 and 29 (approximately study days 44, 57 and 71)]
Systemic clearance (CL) calculated as the average CL value during cycle 1 and cycle 2, where CL = infusion rate (μg/hour) / Css
- Pharmacokinetic (PK) Parameter: Terminal Half-Life [Cycle 1 Day 29: prior to end of infusion and after the end of infusion at 3 hours and 6 hours]
Terminal half-life (t1/2,z) calculated as t1/2,z = ln(2)/lambda-z, where lambda-z was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase from day 29 post-end of infusion collections.
- Pharmacokinetic (PK) Parameter: Volume of Distribution [Cycle 1: Days 2, 15 and 29; Cycle 2: Days 2, 15, and 29 (approximately study days 44, 57 and 71)]
The volume of distribution (Vz) was calculated as Vz = CL/lambda-z, where lambda-z was the first-order rate constant estimated based on cycle 1 day 29 collections via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis and where CL was the CL averaged over multiple cycles. Volume of distribution was estimated for participants who have sufficient evaluable PK data.
- Kaplan-Meier Estimates for Overall Survival (OS) [Interim analysis: From first dose of blinatumomab to the data cutoff date of 12 April 2019; maximum time on follow-up for OS was 14.7 months. Final analysis: From first dose of blinatumomab to end of study; maximum time on follow-up for OS was 25.7 months]
Overall survival time was calculated from the time of first infusion of blinatumomab until death due to any cause. Participants still alive were censored at the date last known to be alive up until the data cut-off date (interim analysis) or end of study date (final analysis). Months are calculated as days from the first treatment to death/censor date, divided by 30.5. Results for both the interim and final analysis are reported.
- Kaplan-Meier Estimate for Relapse-Free Survival (RFS) [Interim Analysis: From first onset of CR/CRh* to the data cutoff date of 12 April 2019; maximum time on follow-up for RFS was 12.4 months. Final Analysis: From first onset of CR/CRh* to end of study; maximum time on follow-up for RFS was 18.1 months.]
Relapse-free survival time was calculated from the first onset of CR/CRh* within the first 2 cycles until the documented hematological relapse, extra-medullary disease, or death due to any cause, whichever occurred first. Participants who were still alive and relapse-free were censored at the date of last disease assessment. Months were calculated as days from the first onset of CR/CRh* within the 2 cycles until the documented hematological relapse/extra-medullary disease/death/censor date, divided by 30.5. Results for both the interim and final analysis are reported.
- Percentage of Participants With Minimal Residual Disease (MRD) Response During the First Two Treatment Cycles [Within 2 cycles of treatment (12 weeks)]
The detection of MRD (the presence of a low number of leukemic cells that are not detectable by light microscopy) after induction therapy and/or consolidation therapy is an independent prognostic factor for poor outcome of ALL. Participants highly responsive to chemotherapy with a MRD-level < 1 × 10^-4 leukemic cells detectable by flow cytometry induced by induction treatment, have a favorable prognosis. MRD response is defined as < 1 ×10^-4 leukemic cells detectable as measured by flow cytometry. MRD complete response is defined as having no detectable leukemic cells by flow cytometry. Results for both the interim and final analysis are reported.
- Percentage of Participants Who Received an Allogenic Hematopoietic Stem Cell Transplant (alloHSCT) After Achieving CR/CRh* During Treatment [Interim analysis: Up to the data cutoff date of 12 April 2019; maximum time on follow-up was 14.7 months. Final analysis: Up to the end of study; maximum time on follow-up was 25.7 months.]
Percentage of participants who underwent allogenic HSCT while in remission among those who responded to treatment by achieving CR/CRh* during treatment. Results for both the interim and final analysis are reported.
- 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant [100 days after HSCT]
The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.
- Kaplan-Meier Estimates for Time to a ≥ Ten-Point Decrease From Baseline in Global Health Status Quality of Life [EORTC QLQ C30 was completed on days 1, 8, 15, and 29 during Cycle 1; days 1, 15, and 29 during cycle 2 and each consolidation cycle, and at the SFU visit (30 days after last dose).]
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales, and 9 symptom scales/items. The GHS is reported in this outcome. For the GHS, scores range from 0 to 100 with a high score indicating better global health status/functioning. A ≥ 10-point decrease from baseline indicates a deterioration in quality of life. Months are calculated from start of blinatumomab date to deterioration/censor date, divided by 30.5.
- Number of Participants With Treatment-Emergent Adverse Events (TEAE) [From day 1 to 30 days after last infusion of blinatumomab; median (min, max) treatment duration was 30.9 (1, 142) days.]
Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.
- Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAE) [From day 1 to 30 days after last infusion of blinatumomab; median (min, max) treatment duration was 30.9 (1, 142) days.]
Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition.
- Participants With Anti-Blinatumomab Antibody Formation [Cycle 2, day 29 (after the completion of Cycle 2) and the SFU visit (30 days after last dose of blinatumomab)]
Anti-blinatumomab binding antibodies were evaluated with a validated blinatumomab anti-drug antibody assay.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects have provided informed consent/assent prior to initiation of any study-specific activities/procedures or subjects legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
-
Subjects with Ph-negative B-precursor ALL, with any of the following:
-
Primary refractory after induction therapy or who had relapsed within 12 months of first remission or
-
Relapsed within 12 months of receiving allogeneic hematopoietic stem cell transplantation (alloHSCT) or
-
Relapsed or refractory after first salvage therapy or beyond
-
5% blasts in bone marrow (by morphology)
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
-
Age ≥ 18 years at the time of informed consent
Exclusion Criteria:
Disease Related
-
Subjects with Ph-positive ALL
-
Subjects with Burkitt´s Leukemia according to World Health Organization (WHO) classification.
-
History or presence of clinically relevant CNS pathology as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis
-
Active ALL in the central nervous system (CNS) (confirmed by cerebrospinal fluid [CSF] analysis) or testes
-
Isolated extramedullary disease
-
Current active autoimmune disease or history of autoimmune disease with potential CNS involvement
Other Medical Conditions
-
History of malignancy other than ALL within 5 years prior to start of protocol-specified therapy with the exception of:
-
Malignancy treated with curative intent and with no known active disease present for 5 years before enrollment and felt to be at low risk for recurrence by the treating physician.
-
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
-
Adequately treated cervical carcinoma in situ without evidence of disease.
-
Adequately treated breast ductal carcinoma in situ without evidence of disease.
-
Prostatic intraepithelial neoplasia without evidence of prostate cancer.
-
Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)
Medications or Other Treatments
-
Autologous HSCT within 6 weeks prior to start of blinatumomab treatment
-
AlloHSCT within 3 months prior to start of blinatumomab treatment
-
Any active acute Graft-versus-Host Disease (GvHD), grade 2-4 according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
-
Any systemic therapy against active GvHD within 2 weeks prior to start of blinatumomab treatment
-
Cancer chemotherapy within 2 weeks prior to start of blinatumomab treatment (intrathecal chemotherapy and dexamethasone are allowed until start of blinatumomab treatment). In addition, any subject whose organ toxicity (excluding hematologic) from prior ALL treatment has not resolved to common terminology criteria for adverse events (CTCAE) ≤ grade 1.
-
Radiotherapy within 2 weeks prior to start of blinatumomab treatment
-
Immunotherapy (eg, rituximab) within 4 weeks prior to start of blinatumomab treatment
-
Currently receiving treatment in another investigational device or drug study, or less than 4 weeks prior to start of blinatumomab treatment.
-
Previous treatment with anti-CD19 therapy
General
-
Known hypersensitivity to immunoglobulins or to any other component of the IMP formulation
-
Pregnant women and women planning to become pregnant should not participate in this study. Subjects who are breast feeding prior to start of blinatumomab treatment may be enrolled if they stop breast feeding with breast milk produced during blinatumomab treatment and for an additional 48 hours after the last dose of blinatumomab.
-
Male participants are not required to use birth control during treatment with blinatumomab. However, you should let your female partner know you are in this study.
-
Subject likely to not be available to complete all protocol-required study visits or procedures, including follow-up visits, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
-
History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
-
Previous treatment with blinatumomab
-
Abnormal screening laboratory values as defined below:
-
Aspartate aminotransferase (AST) and/or alanine aminotransferase ALT and/or alkaline phosphatase (ALP) ≥ 5 * upper limit of normal (ULN)
-
Total bilirubin (TBL) ≥ 1.5 * ULN (unless related to Gilbert´s or Meulengracht disease)
-
Creatinine ≥ 1.5 ULN or creatinine clearance < 60 ml/min (calculated)
-
Woman of childbearing potential and is not willing to use 2 effective methods of contraception during treatment and for an additional 48 hours after the last dose of blinatumomab. Birth control is not required for postmenopausal women, or women with uterus/or both ovaries/ or both fallopian tubes removed.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Peking University Third Hospital | Beijing | Beijing | China | 100191 |
2 | Peking Union Medical College Hospital | Beijing | Beijing | China | 100730 |
3 | Chinese People Liberation Army General Hospital | Beijing | Beijing | China | 100853 |
4 | Fujian Medical University Union Hospital | Fuzhou | Fujian | China | 350001 |
5 | Guangdong Provincial Peoples Hospital | Guangzhou | Guangdong | China | 510080 |
6 | The First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong | China | 510080 |
7 | Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou | Guangdong | China | 510120 |
8 | Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong | China | 510515 |
9 | Henan Cancer Hospital | Zhengzhou | Henan | China | 450008 |
10 | Tongji Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan | Hubei | China | 430030 |
11 | Xiangya Hospital Central South University | Changsha | Hunan | China | 410008 |
12 | Jiangsu Province Hospital | Nanjing | Jiangsu | China | 210029 |
13 | The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China | 215006 |
14 | The First Hospital of Jilin University | Changchun | Jilin | China | 130021 |
15 | The First Hospital of China Medical University | Shenyang | Liaoning | China | 110001 |
16 | The Second Affiliated Hospital of Xi an Jiaotong University | XI An | Shaanxi | China | 71004 |
17 | West China Hospital, Sichuang University | Chengdu | Sichuan | China | 610041 |
18 | Institute of Hematology and Blood Diseases Hospital Peking Union Medical College | Tianjin | Tianjin | China | 300020 |
19 | The First Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou | Zhejiang | China | 310003 |
20 | Second Affiliated Hospital Zhejiang University College of Medicine | Hangzhou | Zhejiang | China | 310009 |
21 | Peking University International Hosipital | Beijing | China | 102206 | |
22 | Anhui Provincial Hospital | Hefei | China | 230001 | |
23 | Huashan Hospital Affiliated to Fudan University | Shanghai | China | 200040 |
Sponsors and Collaborators
- Amgen
Investigators
- Study Director: MD, Amgen
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- 20130316
Study Results
Participant Flow
Recruitment Details | This study was conducted at 23 centers in China. The study included a treatment period, a safety follow-up (SFU) visit 30 days after last dose and a follow-up period. |
---|---|
Pre-assignment Detail | A pre-specified interim analysis was to occur after the first 90 participants had a chance to complete 2 cycles of treatment and safety follow-up; the data cutoff date for this analysis was 12 April 2019. If the pre-specified efficacious benefit criteria were met, the interim analysis would become the primary analysis. A final analysis was conducted once all enrolled participants completed the study. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Period Title: Overall Study | |
STARTED | 121 |
Received Blinatumomab | 120 |
Interim Analysis Set | 90 |
COMPLETED | 23 |
NOT COMPLETED | 98 |
Baseline Characteristics
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Overall Participants | 120 |
Age (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
35.4
(15.2)
|
Age, Customized (Count of Participants) | |
< 35 years |
71
59.2%
|
≥ 35 to < 55 years |
31
25.8%
|
≥ 55 years |
18
15%
|
Age, Customized (Count of Participants) | |
< 65 years |
115
95.8%
|
≥ 65 to < 75 years |
5
4.2%
|
≥ 75 years |
0
0%
|
Sex: Female, Male (Count of Participants) | |
Female |
64
53.3%
|
Male |
56
46.7%
|
Race (NIH/OMB) (Count of Participants) | |
American Indian or Alaska Native |
0
0%
|
Asian |
120
100%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
Black or African American |
0
0%
|
White |
0
0%
|
More than one race |
0
0%
|
Unknown or Not Reported |
0
0%
|
Age at Diagnosis (years) [Mean (Standard Deviation) ] | |
Mean (Standard Deviation) [years] |
34.78
(15.1)
|
Eastern Cooperative Oncology Group (ECOG) Performance Scale (Count of Participants) | |
Status 0 |
43
35.8%
|
Status 1 |
53
44.2%
|
Status 2 |
24
20%
|
Status > 2 |
0
0%
|
Key Entry Criterion (Count of Participants) | |
Criteria #1 |
70
58.3%
|
Criteria #2 |
10
8.3%
|
Criteria #3 |
40
33.3%
|
Outcome Measures
Title | Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab |
---|---|
Description | A CR is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/μL, and absolute neutrophil count [ANC] > 1,000/μL). CRh* is defined as ≤ 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets > 50,000/μl, and ANC > 500/μl. CR/CRh* rate is defined as the percentage of participants who achieve CR/CRh* within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders. The interim analysis was to become the primary analysis by meeting pre-specified efficacy and safety criteria based on an O'Brien-Fleming alpha spending function with the critical boundary 42.2%. Results for both the interim and final analysis are reported. |
Time Frame | Within 2 cycles of treatment (12 weeks) |
Outcome Measure Data
Analysis Population Description |
---|
All enrolled participants who received any infusion of blinatumomab. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 120 |
Interim Analysis |
45.6
38%
|
Final Analysis |
48.3
40.3%
|
Title | Percentage of Participants With a Hematological Response of Complete Remission (CR) During the First 2 Treatment Cycles With Blinatumomab |
---|---|
Description | A CR is defined as having ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets > 100,000/μL, and absolute neutrophil count [ANC] > 1,000/μL). CR rate is defined as the percentage of participants who achieved CR within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders. Results for both the interim and final analysis are reported. |
Time Frame | Within 2 cycles of treatment (12 weeks) |
Outcome Measure Data
Analysis Population Description |
---|
All enrolled participants who received any infusion of blinatumomab. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 120 |
Interim Analysis |
41.1
34.3%
|
Final Analysis |
43.3
36.1%
|
Title | Percentage of Participants With a CR or CRh* or Complete Remission With Incomplete Hematological Recovery Without CRh* (CRi) (CR/CRh*/CRi) During the First 2 Treatment Cycles With Blinatumomab |
---|---|
Description | CRi is defined as ≤ 5% blasts in the bone marrow, no evidence of disease and incomplete recovery of peripheral blood counts: platelets > 100,000/μl or ANC > 1,000/μl (but not both). CR/CRh*/CRi rate is defined as the percentage of participants who achieve CR/CRh*/CRi within 2 cycles of treatment with blinatumomab. Participants without response assessment were accounted for in the denominator when calculating the response rate, ie, these participants were counted as non-responders. Results for both the interim and final analysis are reported. |
Time Frame | Within 2 cycles of treatment (12 weeks) |
Outcome Measure Data
Analysis Population Description |
---|
All enrolled participants who received any infusion of blinatumomab. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 120 |
Interim Analysis |
47.8
39.8%
|
Final Analysis |
50.0
41.7%
|
Title | Pharmacokinetic (PK) Parameter: Concentration of Blinatumomab at Steady State (Css) |
---|---|
Description | Blinatumomab serum concentration was quantified using a validated enzyme- linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 50 pg/mL. Blinatumomab serum steady-state concentrations (Css) was summarized as the average of the observed concentrations collected after 24 hours from the start of continuous IV infusion for each dose level. Cycle 1 day 2 values represent Css for the initial dose of blinatumomab (9 µg/day). Values collected from other time points were used to calculate Css of 28 µg/day dose in their respective cycles. |
Time Frame | Cycle 1: Days 2, 15, and 29; Cycle 2: Days 2, 15, and 29 (approximately study days 44, 57, and 71) |
Outcome Measure Data
Analysis Population Description |
---|
Pharmacokinetic analysis set consisting of all participants who received blinatumomab and had at least one PK sample collected. The number of participants analyzed for each time point reflects participants with available Css data; data below the lower limit of quantification and from subjects who did not receive the specified doses were excluded. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 118 |
Cycle 1: 9 μg/day |
103
(41)
|
Cycle 1: 28 μg/day |
416
(72)
|
Cycle 2: 28 μg/day |
634
(21)
|
Title | Pharmacokinetic (PK) Parameter: Clearance |
---|---|
Description | Systemic clearance (CL) calculated as the average CL value during cycle 1 and cycle 2, where CL = infusion rate (μg/hour) / Css |
Time Frame | Cycle 1: Days 2, 15 and 29; Cycle 2: Days 2, 15 and 29 (approximately study days 44, 57 and 71) |
Outcome Measure Data
Analysis Population Description |
---|
Participants in the pharmacokinetic analysis set with available CL data at at least one post-baseline time point; data below the lower limit of quantification and from participants who did not receive the specified doses were excluded. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 108 |
Geometric Mean (Geometric Coefficient of Variation) [L/hour] |
2.86
(57)
|
Title | Pharmacokinetic (PK) Parameter: Terminal Half-Life |
---|---|
Description | Terminal half-life (t1/2,z) calculated as t1/2,z = ln(2)/lambda-z, where lambda-z was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase from day 29 post-end of infusion collections. |
Time Frame | Cycle 1 Day 29: prior to end of infusion and after the end of infusion at 3 hours and 6 hours |
Outcome Measure Data
Analysis Population Description |
---|
Participants in the pharmacokinetic analysis set with sufficient data on cycle 1 day 29 to calculate half-life. Data below the lower limit of quantification and from participants who did not receive the specified doses were excluded. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 9 |
Geometric Mean (Geometric Coefficient of Variation) [hours] |
2.22
(31)
|
Title | Pharmacokinetic (PK) Parameter: Volume of Distribution |
---|---|
Description | The volume of distribution (Vz) was calculated as Vz = CL/lambda-z, where lambda-z was the first-order rate constant estimated based on cycle 1 day 29 collections via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis and where CL was the CL averaged over multiple cycles. Volume of distribution was estimated for participants who have sufficient evaluable PK data. |
Time Frame | Cycle 1: Days 2, 15 and 29; Cycle 2: Days 2, 15, and 29 (approximately study days 44, 57 and 71) |
Outcome Measure Data
Analysis Population Description |
---|
Participants in the pharmacokinetic analysis set with sufficient data to calculate volume of distribution. Data below the lower limit of quantification and from participants who did not receive the specified doses were excluded. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 9 |
Geometric Mean (Geometric Coefficient of Variation) [liters] |
7.15
(61)
|
Title | Kaplan-Meier Estimates for Overall Survival (OS) |
---|---|
Description | Overall survival time was calculated from the time of first infusion of blinatumomab until death due to any cause. Participants still alive were censored at the date last known to be alive up until the data cut-off date (interim analysis) or end of study date (final analysis). Months are calculated as days from the first treatment to death/censor date, divided by 30.5. Results for both the interim and final analysis are reported. |
Time Frame | Interim analysis: From first dose of blinatumomab to the data cutoff date of 12 April 2019; maximum time on follow-up for OS was 14.7 months. Final analysis: From first dose of blinatumomab to end of study; maximum time on follow-up for OS was 25.7 months |
Outcome Measure Data
Analysis Population Description |
---|
All enrolled participants who received any infusion of blinatumomab. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 120 |
Interim Analysis |
9.2
|
Final Analysis |
9.1
|
Title | Kaplan-Meier Estimate for Relapse-Free Survival (RFS) |
---|---|
Description | Relapse-free survival time was calculated from the first onset of CR/CRh* within the first 2 cycles until the documented hematological relapse, extra-medullary disease, or death due to any cause, whichever occurred first. Participants who were still alive and relapse-free were censored at the date of last disease assessment. Months were calculated as days from the first onset of CR/CRh* within the 2 cycles until the documented hematological relapse/extra-medullary disease/death/censor date, divided by 30.5. Results for both the interim and final analysis are reported. |
Time Frame | Interim Analysis: From first onset of CR/CRh* to the data cutoff date of 12 April 2019; maximum time on follow-up for RFS was 12.4 months. Final Analysis: From first onset of CR/CRh* to end of study; maximum time on follow-up for RFS was 18.1 months. |
Outcome Measure Data
Analysis Population Description |
---|
Enrolled participants who received any infusion of blinatumomab who achieved CR/CRh* during the first 2 cycles. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit and who achieved CR/CRh* during the first 2 cycles. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 58 |
Interim Analysis |
4.3
|
Final Analysis |
5.4
|
Title | Percentage of Participants With Minimal Residual Disease (MRD) Response During the First Two Treatment Cycles |
---|---|
Description | The detection of MRD (the presence of a low number of leukemic cells that are not detectable by light microscopy) after induction therapy and/or consolidation therapy is an independent prognostic factor for poor outcome of ALL. Participants highly responsive to chemotherapy with a MRD-level < 1 × 10^-4 leukemic cells detectable by flow cytometry induced by induction treatment, have a favorable prognosis. MRD response is defined as < 1 ×10^-4 leukemic cells detectable as measured by flow cytometry. MRD complete response is defined as having no detectable leukemic cells by flow cytometry. Results for both the interim and final analysis are reported. |
Time Frame | Within 2 cycles of treatment (12 weeks) |
Outcome Measure Data
Analysis Population Description |
---|
Participants who received any infusion of blinatumomab who achieved CR/CRh* within 2 cycles and had evaluable MRD assessment. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit who achieved CR/CRh* within 2 cycles and had evaluable MRD assessment. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 58 |
Interim Analysis: MRD Response |
82.9
69.1%
|
Interim Analysis: MRD Complete Response |
2.4
2%
|
Final Analysis: MRD Response |
84.5
70.4%
|
Final Analysis: MRD Complete Response |
1.7
1.4%
|
Title | Percentage of Participants Who Received an Allogenic Hematopoietic Stem Cell Transplant (alloHSCT) After Achieving CR/CRh* During Treatment |
---|---|
Description | Percentage of participants who underwent allogenic HSCT while in remission among those who responded to treatment by achieving CR/CRh* during treatment. Results for both the interim and final analysis are reported. |
Time Frame | Interim analysis: Up to the data cutoff date of 12 April 2019; maximum time on follow-up was 14.7 months. Final analysis: Up to the end of study; maximum time on follow-up was 25.7 months. |
Outcome Measure Data
Analysis Population Description |
---|
Enrolled participants who received any infusion of blinatumomab who achieved CR/CRh* during treatment. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit and who achieved CR/CRh* during treatment. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 58 |
Interim Analysis |
22.0
18.3%
|
Final Analysis |
27.6
23%
|
Title | 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant |
---|---|
Description | The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. |
Time Frame | 100 days after HSCT |
Outcome Measure Data
Analysis Population Description |
---|
Participants who received any infusion of blinatumomab with a CR/CRh* response who underwent alloHSCT while in remission. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit, achieved CR/CRh* and underwent alloHSCT while in remission. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 15 |
Interim Analysis |
0.0
0%
|
Final Analysis |
6.7
5.6%
|
Title | Kaplan-Meier Estimates for Time to a ≥ Ten-Point Decrease From Baseline in Global Health Status Quality of Life |
---|---|
Description | The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales, and 9 symptom scales/items. The GHS is reported in this outcome. For the GHS, scores range from 0 to 100 with a high score indicating better global health status/functioning. A ≥ 10-point decrease from baseline indicates a deterioration in quality of life. Months are calculated from start of blinatumomab date to deterioration/censor date, divided by 30.5. |
Time Frame | EORTC QLQ C30 was completed on days 1, 8, 15, and 29 during Cycle 1; days 1, 15, and 29 during cycle 2 and each consolidation cycle, and at the SFU visit (30 days after last dose). |
Outcome Measure Data
Analysis Population Description |
---|
Participants who received blinatumomab treatment and had baseline and ≥ 1 postbaseline result for EORTC QLQ-C30 GHS. The interim analysis was based on the first 90 participants who had a chance to complete ≥ 2 cycles of blinatumomab and the safety follow-up visit who had a baseline and ≥ 1 postbaseline result for EORTC QLQ-C30 GHS. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 110 |
Interim Analysis |
1.6
|
Final Analysis |
3.7
|
Title | Number of Participants With Treatment-Emergent Adverse Events (TEAE) |
---|---|
Description | Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition. |
Time Frame | From day 1 to 30 days after last infusion of blinatumomab; median (min, max) treatment duration was 30.9 (1, 142) days. |
Outcome Measure Data
Analysis Population Description |
---|
All enrolled participants who received any infusion of blinatumomab. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 120 |
Any TEAE |
120
100%
|
TEAE Grade ≥ 3 |
115
95.8%
|
Serious AE |
40
33.3%
|
TEAE leading to drug discontinuation |
18
15%
|
Serious AE leading to drug discontinuation |
12
10%
|
TEAE leading to drug interruption |
31
25.8%
|
Serious AE leading to drug interruption |
13
10.8%
|
Fatal AE |
11
9.2%
|
Title | Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAE) |
---|---|
Description | Adverse events (AEs) were evaluated for severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions, was a congenital anomaly or birth defect or was a medically important condition. |
Time Frame | From day 1 to 30 days after last infusion of blinatumomab; median (min, max) treatment duration was 30.9 (1, 142) days. |
Outcome Measure Data
Analysis Population Description |
---|
All enrolled participants who received any infusion of blinatumomab. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 120 |
Any Treatment-related TEAE |
118
98.3%
|
Related TEAE Grade ≥ 3 |
99
82.5%
|
Related Serious AE (SAE) |
29
24.2%
|
Related TEAE leading to drug discontinuation |
16
13.3%
|
Related SAE leading to drug discontinuation |
11
9.2%
|
Related TEAE leading to drug interruption |
25
20.8%
|
Related SAE leading to drug interruption |
10
8.3%
|
Related fatal AE |
6
5%
|
Title | Participants With Anti-Blinatumomab Antibody Formation |
---|---|
Description | Anti-blinatumomab binding antibodies were evaluated with a validated blinatumomab anti-drug antibody assay. |
Time Frame | Cycle 2, day 29 (after the completion of Cycle 2) and the SFU visit (30 days after last dose of blinatumomab) |
Outcome Measure Data
Analysis Population Description |
---|
Enrolled participants who received any infusion of blinatumomab with available post-baseline antibody results. |
Arm/Group Title | Blinatumomab |
---|---|
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. |
Measure Participants | 91 |
Binding antibody positive at anytime |
0
0%
|
Neutralizing antibody positive at anytime |
0
0%
|
Adverse Events
Time Frame | Mortality data are reported from enrollment to the end of study, maximum time on study was 26 months. Adverse events are reported from day 1 to 30 days after last infusion of blinatumomab; the median (min, max) treatment duration was 30.9 (1, 142) days. | |
---|---|---|
Adverse Event Reporting Description | All-cause mortality is reported for all participants enrolled in the study. Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug. | |
Arm/Group Title | Blinatumomab | |
Arm/Group Description | Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders. In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4), followed by two weeks without blinatumomab treatment. In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks. | |
All Cause Mortality |
||
Blinatumomab | ||
Affected / at Risk (%) | # Events | |
Total | 81/121 (66.9%) | |
Serious Adverse Events |
||
Blinatumomab | ||
Affected / at Risk (%) | # Events | |
Total | 40/120 (33.3%) | |
Blood and lymphatic system disorders | ||
Anaemia | 2/120 (1.7%) | |
Disseminated intravascular coagulation | 1/120 (0.8%) | |
Neutropenia | 1/120 (0.8%) | |
Cardiac disorders | ||
Cardiac arrest | 1/120 (0.8%) | |
Cardiac failure acute | 1/120 (0.8%) | |
Ear and labyrinth disorders | ||
Hypoacusis | 1/120 (0.8%) | |
Gastrointestinal disorders | ||
Gastrointestinal haemorrhage | 1/120 (0.8%) | |
Pancreatitis acute | 1/120 (0.8%) | |
Hepatobiliary disorders | ||
Liver injury | 3/120 (2.5%) | |
Immune system disorders | ||
Cytokine release syndrome | 5/120 (4.2%) | |
Infections and infestations | ||
Candida infection | 1/120 (0.8%) | |
Cytomegalovirus urinary tract infection | 1/120 (0.8%) | |
Device related infection | 1/120 (0.8%) | |
Neutropenic infection | 1/120 (0.8%) | |
Pneumonia | 5/120 (4.2%) | |
Respiratory tract infection | 2/120 (1.7%) | |
Sepsis | 1/120 (0.8%) | |
Fungaemia | 1/120 (0.8%) | |
Infection | 1/120 (0.8%) | |
Investigations | ||
Aspartate aminotransferase increased | 1/120 (0.8%) | |
Neutrophil count decreased | 1/120 (0.8%) | |
Platelet count decreased | 2/120 (1.7%) | |
White blood cell count decreased | 1/120 (0.8%) | |
Metabolism and nutrition disorders | ||
Hypercalcaemia | 1/120 (0.8%) | |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||
Acute lymphocytic leukaemia | 2/120 (1.7%) | |
Central nervous system leukaemia | 3/120 (2.5%) | |
Transformation to acute myeloid leukaemia | 1/120 (0.8%) | |
Nervous system disorders | ||
Haemorrhage intracranial | 2/120 (1.7%) | |
Epilepsy | 1/120 (0.8%) | |
Respiratory, thoracic and mediastinal disorders | ||
Interstitial lung disease | 1/120 (0.8%) | |
Pneumonitis | 1/120 (0.8%) | |
Respiratory failure | 1/120 (0.8%) | |
Other (Not Including Serious) Adverse Events |
||
Blinatumomab | ||
Affected / at Risk (%) | # Events | |
Total | 120/120 (100%) | |
Blood and lymphatic system disorders | ||
Anaemia | 76/120 (63.3%) | |
Coagulopathy | 13/120 (10.8%) | |
Leukocytosis | 15/120 (12.5%) | |
Leukopenia | 38/120 (31.7%) | |
Lymphocytosis | 6/120 (5%) | |
Lymphopenia | 18/120 (15%) | |
Neutropenia | 30/120 (25%) | |
Thrombocytopenia | 37/120 (30.8%) | |
Blood disorder | 6/120 (5%) | |
Cardiac disorders | ||
Sinus tachycardia | 6/120 (5%) | |
Gastrointestinal disorders | ||
Abdominal distension | 10/120 (8.3%) | |
Constipation | 15/120 (12.5%) | |
Diarrhoea | 15/120 (12.5%) | |
Haemorrhoids | 6/120 (5%) | |
Mouth ulceration | 7/120 (5.8%) | |
Nausea | 14/120 (11.7%) | |
Vomiting | 15/120 (12.5%) | |
Toothache | 6/120 (5%) | |
General disorders | ||
Asthenia | 13/120 (10.8%) | |
Chest pain | 6/120 (5%) | |
Oedema peripheral | 13/120 (10.8%) | |
Pyrexia | 57/120 (47.5%) | |
Hepatobiliary disorders | ||
Hepatic function abnormal | 12/120 (10%) | |
Liver injury | 14/120 (11.7%) | |
Immune system disorders | ||
Cytokine release syndrome | 71/120 (59.2%) | |
Infections and infestations | ||
Infection | 8/120 (6.7%) | |
Pneumonia | 26/120 (21.7%) | |
Upper respiratory tract infection | 21/120 (17.5%) | |
Urinary tract infection | 7/120 (5.8%) | |
Folliculitis | 6/120 (5%) | |
Investigations | ||
Activated partial thromboplastin time prolonged | 12/120 (10%) | |
Alanine aminotransferase increased | 28/120 (23.3%) | |
Albumin globulin ratio increased | 6/120 (5%) | |
Alpha hydroxybutyrate dehydrogenase increased | 17/120 (14.2%) | |
Anion gap increased | 6/120 (5%) | |
Aspartate aminotransferase increased | 32/120 (26.7%) | |
Beta 2 microglobulin increased | 7/120 (5.8%) | |
Bilirubin conjugated increased | 18/120 (15%) | |
Blast cell count increased | 7/120 (5.8%) | |
Blood albumin decreased | 22/120 (18.3%) | |
Blood alkaline phosphatase increased | 18/120 (15%) | |
Blood bilirubin increased | 23/120 (19.2%) | |
Blood calcium decreased | 13/120 (10.8%) | |
Blood fibrinogen decreased | 9/120 (7.5%) | |
Blood fibrinogen increased | 15/120 (12.5%) | |
Blood glucose increased | 22/120 (18.3%) | |
Blood immunoglobulin A decreased | 20/120 (16.7%) | |
Blood immunoglobulin G decreased | 34/120 (28.3%) | |
Blood immunoglobulin M decreased | 18/120 (15%) | |
Blood lactate dehydrogenase increased | 54/120 (45%) | |
Blood phosphorus increased | 14/120 (11.7%) | |
Blood potassium decreased | 10/120 (8.3%) | |
Blood triglycerides increased | 14/120 (11.7%) | |
Blood urea increased | 9/120 (7.5%) | |
Blood uric acid increased | 15/120 (12.5%) | |
C-reactive protein increased | 60/120 (50%) | |
Eosinophil count decreased | 8/120 (6.7%) | |
Fibrin D dimer increased | 29/120 (24.2%) | |
Fibrin degradation products increased | 8/120 (6.7%) | |
Gamma-glutamyltransferase increased | 33/120 (27.5%) | |
Globulins decreased | 22/120 (18.3%) | |
Haematocrit decreased | 7/120 (5.8%) | |
Haemoglobin decreased | 8/120 (6.7%) | |
Immunoglobulins decreased | 18/120 (15%) | |
Interleukin level increased | 21/120 (17.5%) | |
International normalised ratio increased | 6/120 (5%) | |
Lymphocyte count decreased | 57/120 (47.5%) | |
Lymphocyte count increased | 15/120 (12.5%) | |
Lymphocyte percentage decreased | 11/120 (9.2%) | |
Lymphocyte percentage increased | 6/120 (5%) | |
Monocyte count decreased | 22/120 (18.3%) | |
Monocyte percentage decreased | 6/120 (5%) | |
Neutrophil count decreased | 58/120 (48.3%) | |
Neutrophil count increased | 19/120 (15.8%) | |
Neutrophil percentage decreased | 9/120 (7.5%) | |
Neutrophil percentage increased | 8/120 (6.7%) | |
Platelet count decreased | 53/120 (44.2%) | |
Procalcitonin increased | 21/120 (17.5%) | |
Protein total decreased | 21/120 (17.5%) | |
Red blood cell count decreased | 13/120 (10.8%) | |
Reticulocyte count decreased | 7/120 (5.8%) | |
Reticulocyte count increased | 17/120 (14.2%) | |
Serum ferritin increased | 14/120 (11.7%) | |
White blood cell count decreased | 65/120 (54.2%) | |
White blood cell count increased | 25/120 (20.8%) | |
Blood cholesterol increased | 6/120 (5%) | |
Blood phosphorus decreased | 6/120 (5%) | |
Monocyte count increased | 6/120 (5%) | |
Reticulocyte percentage increased | 9/120 (7.5%) | |
Metabolism and nutrition disorders | ||
Decreased appetite | 8/120 (6.7%) | |
Hyperglycaemia | 23/120 (19.2%) | |
Hypertriglyceridaemia | 15/120 (12.5%) | |
Hyperuricaemia | 24/120 (20%) | |
Hypoalbuminaemia | 22/120 (18.3%) | |
Hypocalcaemia | 27/120 (22.5%) | |
Hypoglycaemia | 8/120 (6.7%) | |
Hypokalaemia | 62/120 (51.7%) | |
Hypomagnesaemia | 10/120 (8.3%) | |
Hyponatraemia | 14/120 (11.7%) | |
Hypophosphataemia | 14/120 (11.7%) | |
Hypoproteinaemia | 21/120 (17.5%) | |
Hyperlipidaemia | 8/120 (6.7%) | |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 14/120 (11.7%) | |
Bone pain | 9/120 (7.5%) | |
Pain in extremity | 6/120 (5%) | |
Nervous system disorders | ||
Dizziness | 11/120 (9.2%) | |
Headache | 10/120 (8.3%) | |
Psychiatric disorders | ||
Insomnia | 11/120 (9.2%) | |
Respiratory, thoracic and mediastinal disorders | ||
Cough | 15/120 (12.5%) | |
Epistaxis | 9/120 (7.5%) | |
Hypoxia | 6/120 (5%) | |
Oropharyngeal pain | 9/120 (7.5%) | |
Skin and subcutaneous tissue disorders | ||
Rash | 13/120 (10.8%) | |
Pruritus | 6/120 (5%) | |
Vascular disorders | ||
Hypotension | 7/120 (5.8%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
Results Point of Contact
Name/Title | Study Director |
---|---|
Organization | Amgen Inc. |
Phone | 866-572-6436 |
medinfo@amgen.com |
- 20130316